Armata posts Q1 net loss of $115.3M ($3.16/diluted share); secures $25M Innoviva loan

Armata Pharmaceuticals, Inc.

Net loss of $115.3M vs $6.5M in Q1 2025; loss includes non-cash items from warrant amendments.
Revenue of $0.8M (grant) up from $0.5M; R&D spend $6.1M vs $5.4M; cash $4.8M down from $8.7M.
Entered $25M secured term loan with Innoviva at 14% interest, maturing Jan 11, 2029.
AP-SA02 Phase 3 superiority study in S. aureus bacteremia expected to start H2 2026; FDA granted QIDP and Fast Track.
Appointed Daniel Gilmer to Board; ~36.7M shares outstanding as of May 8, 2026.

item 1.01item 2.02item 2.03item 7.01item 9.01

Source: SEC EDGAR

accession 0001104659-26-060299

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.